| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intracranial Arteriosclerosis | 32 | 2022 | 134 | 9.510 |
Why?
|
| Stroke | 72 | 2023 | 2163 | 6.760 |
Why?
|
| Stents | 28 | 2022 | 657 | 3.750 |
Why?
|
| Carotid Stenosis | 10 | 2021 | 163 | 2.960 |
Why?
|
| Angioplasty | 17 | 2022 | 118 | 2.900 |
Why?
|
| Atherosclerosis | 6 | 2021 | 204 | 2.430 |
Why?
|
| Constriction, Pathologic | 25 | 2022 | 236 | 2.430 |
Why?
|
| Fibrinolytic Agents | 13 | 2020 | 377 | 2.270 |
Why?
|
| Secondary Prevention | 13 | 2022 | 291 | 2.230 |
Why?
|
| Vertebrobasilar Insufficiency | 5 | 2017 | 21 | 1.920 |
Why?
|
| Blood Pressure | 11 | 2022 | 1451 | 1.800 |
Why?
|
| Ischemic Attack, Transient | 15 | 2022 | 167 | 1.780 |
Why?
|
| Intracranial Arterial Diseases | 4 | 2017 | 15 | 1.530 |
Why?
|
| American Heart Association | 15 | 2021 | 142 | 1.370 |
Why?
|
| Risk Reduction Behavior | 8 | 2021 | 174 | 1.340 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2021 | 2223 | 1.290 |
Why?
|
| Neurology | 3 | 2020 | 43 | 1.280 |
Why?
|
| Risk Factors | 35 | 2023 | 5731 | 1.250 |
Why?
|
| Treatment Outcome | 35 | 2023 | 7029 | 1.100 |
Why?
|
| Lipoproteins, LDL | 2 | 2020 | 343 | 1.090 |
Why?
|
| Humans | 102 | 2023 | 68618 | 1.070 |
Why?
|
| Endovascular Procedures | 5 | 2017 | 366 | 1.020 |
Why?
|
| Exercise | 3 | 2019 | 658 | 0.960 |
Why?
|
| Heart Diseases | 11 | 2016 | 276 | 0.960 |
Why?
|
| Cognition | 3 | 2019 | 513 | 0.940 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 82 | 0.930 |
Why?
|
| Anticoagulants | 6 | 2017 | 356 | 0.930 |
Why?
|
| Cerebral Arterial Diseases | 5 | 2013 | 28 | 0.930 |
Why?
|
| Research Design | 5 | 2020 | 729 | 0.910 |
Why?
|
| Hypertension | 8 | 2022 | 1535 | 0.900 |
Why?
|
| Cerebral Hemorrhage | 6 | 2018 | 198 | 0.820 |
Why?
|
| Venous Thrombosis | 2 | 2017 | 125 | 0.810 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2022 | 373 | 0.770 |
Why?
|
| Brain Ischemia | 10 | 2021 | 665 | 0.770 |
Why?
|
| Recurrence | 14 | 2020 | 948 | 0.770 |
Why?
|
| Aspirin | 10 | 2022 | 295 | 0.760 |
Why?
|
| Magnetic Resonance Angiography | 5 | 2017 | 181 | 0.740 |
Why?
|
| Life Style | 2 | 2020 | 338 | 0.740 |
Why?
|
| Ophthalmology | 1 | 2020 | 39 | 0.730 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2020 | 54 | 0.730 |
Why?
|
| Brain | 7 | 2018 | 2176 | 0.720 |
Why?
|
| Middle Aged | 44 | 2022 | 21147 | 0.710 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 89 | 0.700 |
Why?
|
| Female | 52 | 2022 | 38074 | 0.670 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2017 | 41 | 0.670 |
Why?
|
| United States | 27 | 2021 | 7367 | 0.650 |
Why?
|
| Appetite Depressants | 1 | 2018 | 11 | 0.640 |
Why?
|
| Phentermine | 1 | 2018 | 17 | 0.630 |
Why?
|
| Endometrial Neoplasms | 2 | 2015 | 69 | 0.610 |
Why?
|
| Diagnostic Imaging | 3 | 2016 | 201 | 0.610 |
Why?
|
| Research Report | 6 | 2016 | 35 | 0.610 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2022 | 931 | 0.600 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 504 | 0.600 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2015 | 125 | 0.590 |
Why?
|
| Aged | 36 | 2022 | 14862 | 0.580 |
Why?
|
| Smoking | 5 | 2023 | 1452 | 0.580 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2017 | 333 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 212 | 0.580 |
Why?
|
| Postprandial Period | 1 | 2017 | 21 | 0.570 |
Why?
|
| Hemiplegia | 1 | 2017 | 29 | 0.570 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2022 | 28 | 0.570 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 122 | 0.570 |
Why?
|
| Exercise Therapy | 1 | 2019 | 183 | 0.560 |
Why?
|
| Thrombosis | 2 | 2017 | 218 | 0.560 |
Why?
|
| Carotid Artery Diseases | 1 | 2017 | 83 | 0.540 |
Why?
|
| Blood Vessels | 1 | 2016 | 102 | 0.540 |
Why?
|
| Light | 1 | 2017 | 152 | 0.540 |
Why?
|
| Angioplasty, Balloon | 2 | 2017 | 110 | 0.530 |
Why?
|
| Male | 45 | 2022 | 37321 | 0.530 |
Why?
|
| Phantoms, Imaging | 1 | 2017 | 189 | 0.530 |
Why?
|
| Endometrial Hyperplasia | 1 | 2015 | 4 | 0.530 |
Why?
|
| Follow-Up Studies | 19 | 2022 | 3259 | 0.520 |
Why?
|
| Cognitive Dysfunction | 1 | 2019 | 176 | 0.520 |
Why?
|
| Premenopause | 1 | 2015 | 57 | 0.520 |
Why?
|
| Hemorrhage | 4 | 2023 | 328 | 0.520 |
Why?
|
| Age Factors | 3 | 2020 | 1864 | 0.510 |
Why?
|
| Postmenopause | 1 | 2015 | 93 | 0.510 |
Why?
|
| Antihypertensive Agents | 7 | 2022 | 498 | 0.500 |
Why?
|
| Time Factors | 11 | 2021 | 4655 | 0.500 |
Why?
|
| Patient Compliance | 1 | 2017 | 402 | 0.500 |
Why?
|
| Radiology, Interventional | 1 | 2014 | 21 | 0.460 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 50 | 0.460 |
Why?
|
| Carotid Artery, Common | 1 | 2013 | 25 | 0.460 |
Why?
|
| Cognition Disorders | 1 | 2016 | 342 | 0.450 |
Why?
|
| Disease Management | 4 | 2020 | 248 | 0.430 |
Why?
|
| Cerebral Angiography | 5 | 2017 | 151 | 0.420 |
Why?
|
| Postoperative Complications | 4 | 2017 | 1615 | 0.410 |
Why?
|
| Warfarin | 5 | 2014 | 93 | 0.390 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 1851 | 0.360 |
Why?
|
| Leukoencephalopathies | 2 | 2021 | 13 | 0.360 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 546 | 0.350 |
Why?
|
| Thrombectomy | 4 | 2021 | 238 | 0.340 |
Why?
|
| Pre-Eclampsia | 2 | 2022 | 202 | 0.340 |
Why?
|
| Middle Cerebral Artery | 4 | 2020 | 57 | 0.340 |
Why?
|
| Ticlopidine | 6 | 2015 | 118 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 772 | 0.320 |
Why?
|
| Risk Assessment | 7 | 2020 | 2007 | 0.320 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2077 | 0.310 |
Why?
|
| Arteries | 2 | 2022 | 108 | 0.310 |
Why?
|
| Cerebrovascular Disorders | 1 | 2008 | 182 | 0.300 |
Why?
|
| Cerebral Revascularization | 1 | 2008 | 45 | 0.300 |
Why?
|
| Retinal Vein Occlusion | 1 | 2007 | 1 | 0.290 |
Why?
|
| Drug Therapy, Combination | 5 | 2021 | 649 | 0.290 |
Why?
|
| Thrombolytic Therapy | 1 | 2009 | 233 | 0.290 |
Why?
|
| Patient Selection | 4 | 2020 | 592 | 0.290 |
Why?
|
| Prospective Studies | 10 | 2021 | 3705 | 0.280 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2006 | 3 | 0.270 |
Why?
|
| Data Interpretation, Statistical | 4 | 2016 | 329 | 0.270 |
Why?
|
| Risk | 4 | 2017 | 563 | 0.260 |
Why?
|
| Myocardial Infarction | 2 | 2023 | 807 | 0.240 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 940 | 0.240 |
Why?
|
| Intracranial Hypotension | 1 | 2004 | 4 | 0.240 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2004 | 20 | 0.240 |
Why?
|
| Intracranial Hypertension | 1 | 2004 | 53 | 0.230 |
Why?
|
| Biomarkers | 2 | 2020 | 1593 | 0.220 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 4848 | 0.210 |
Why?
|
| Cerebrovascular Circulation | 3 | 2014 | 296 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 468 | 0.210 |
Why?
|
| Cardiology | 2 | 2014 | 140 | 0.210 |
Why?
|
| Dihydropyridines | 1 | 2022 | 13 | 0.210 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1465 | 0.200 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 1 | 2021 | 2 | 0.200 |
Why?
|
| Neurosurgical Procedures | 2 | 2013 | 98 | 0.200 |
Why?
|
| Pregnancy | 6 | 2022 | 2334 | 0.200 |
Why?
|
| Eclampsia | 1 | 2021 | 16 | 0.200 |
Why?
|
| Prevalence | 5 | 2019 | 1619 | 0.200 |
Why?
|
| Adult | 13 | 2021 | 21403 | 0.190 |
Why?
|
| Ophthalmologists | 1 | 2020 | 2 | 0.190 |
Why?
|
| Brain Injuries | 1 | 2004 | 268 | 0.190 |
Why?
|
| Prehypertension | 1 | 2021 | 40 | 0.190 |
Why?
|
| Foramen Ovale, Patent | 2 | 2018 | 21 | 0.180 |
Why?
|
| Aneurysm, Ruptured | 1 | 2010 | 40 | 0.170 |
Why?
|
| Therapeutic Equipoise | 1 | 2019 | 3 | 0.170 |
Why?
|
| Neurologists | 1 | 2019 | 15 | 0.170 |
Why?
|
| Carotid Artery, Internal | 2 | 2020 | 85 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 848 | 0.160 |
Why?
|
| Kidney Diseases | 1 | 2022 | 307 | 0.160 |
Why?
|
| Guideline Adherence | 1 | 2021 | 287 | 0.160 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 219 | 0.160 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 139 | 0.160 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2011 | 134 | 0.160 |
Why?
|
| Obesity | 2 | 2018 | 1076 | 0.160 |
Why?
|
| Drug Utilization | 2 | 2021 | 119 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 652 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1046 | 0.160 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 2800 | 0.160 |
Why?
|
| White Matter | 1 | 2021 | 174 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 275 | 0.160 |
Why?
|
| Pipecolic Acids | 1 | 2017 | 9 | 0.150 |
Why?
|
| Platelet Count | 1 | 2017 | 100 | 0.150 |
Why?
|
| Health Care Surveys | 2 | 2019 | 239 | 0.150 |
Why?
|
| Lateral Medullary Syndrome | 1 | 2017 | 2 | 0.150 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2017 | 6 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 143 | 0.140 |
Why?
|
| Arginine | 1 | 2017 | 102 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 154 | 0.140 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 36 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2022 | 7277 | 0.140 |
Why?
|
| Telephone | 1 | 2017 | 160 | 0.140 |
Why?
|
| Self Report | 1 | 2019 | 371 | 0.140 |
Why?
|
| Sulfonamides | 1 | 2017 | 141 | 0.140 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2017 | 52 | 0.140 |
Why?
|
| Endarterectomy, Carotid | 1 | 2017 | 110 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 352 | 0.140 |
Why?
|
| Asymptomatic Diseases | 3 | 2021 | 43 | 0.140 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2016 | 10 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2014 | 951 | 0.130 |
Why?
|
| Frozen Sections | 1 | 2015 | 14 | 0.130 |
Why?
|
| Recovery of Function | 2 | 2016 | 506 | 0.130 |
Why?
|
| Counseling | 1 | 2017 | 280 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 507 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 47 | 0.130 |
Why?
|
| Cholesterol | 1 | 2016 | 331 | 0.130 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.120 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 696 | 0.120 |
Why?
|
| Smartphone | 1 | 2015 | 69 | 0.120 |
Why?
|
| Vertebral Artery | 2 | 2020 | 22 | 0.120 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 33 | 0.120 |
Why?
|
| Hysterectomy | 1 | 2014 | 64 | 0.120 |
Why?
|
| Health Behavior | 2 | 2016 | 458 | 0.120 |
Why?
|
| Uterus | 1 | 2014 | 77 | 0.120 |
Why?
|
| Basilar Artery | 2 | 2020 | 38 | 0.120 |
Why?
|
| Neuropsychological Tests | 1 | 2016 | 517 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 91 | 0.120 |
Why?
|
| Electrocardiography | 1 | 2017 | 601 | 0.120 |
Why?
|
| Patient Participation | 1 | 2015 | 146 | 0.120 |
Why?
|
| Voluntary Health Agencies | 1 | 2013 | 4 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 237 | 0.110 |
Why?
|
| Incidence | 5 | 2021 | 1603 | 0.110 |
Why?
|
| Survival Analysis | 3 | 2014 | 714 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2014 | 258 | 0.110 |
Why?
|
| Body Mass Index | 1 | 2016 | 867 | 0.110 |
Why?
|
| Carcinoma | 1 | 2014 | 215 | 0.110 |
Why?
|
| Logistic Models | 1 | 2016 | 1420 | 0.110 |
Why?
|
| Perioperative Period | 1 | 2012 | 24 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 536 | 0.100 |
Why?
|
| Internet | 1 | 2015 | 390 | 0.100 |
Why?
|
| Heart Failure | 1 | 2021 | 1180 | 0.100 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 168 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 27 | 0.100 |
Why?
|
| Survival Rate | 3 | 2021 | 1056 | 0.100 |
Why?
|
| Central Nervous System Diseases | 1 | 2011 | 40 | 0.100 |
Why?
|
| Collateral Circulation | 1 | 2011 | 34 | 0.100 |
Why?
|
| Spain | 2 | 2021 | 34 | 0.090 |
Why?
|
| Macrophages | 1 | 2014 | 647 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2011 | 77 | 0.090 |
Why?
|
| Calcium | 1 | 2014 | 929 | 0.090 |
Why?
|
| Stroke Rehabilitation | 1 | 2014 | 335 | 0.090 |
Why?
|
| Angiography | 1 | 2010 | 194 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2012 | 249 | 0.090 |
Why?
|
| Adolescent | 5 | 2021 | 8912 | 0.080 |
Why?
|
| Radiography | 1 | 2010 | 572 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2008 | 82 | 0.080 |
Why?
|
| Double-Blind Method | 2 | 2011 | 1738 | 0.080 |
Why?
|
| Young Adult | 5 | 2021 | 5717 | 0.080 |
Why?
|
| Evidence-Based Medicine | 3 | 2021 | 438 | 0.080 |
Why?
|
| Carotid Arteries | 1 | 2008 | 110 | 0.070 |
Why?
|
| Dyslipidemias | 2 | 2020 | 98 | 0.070 |
Why?
|
| Systole | 1 | 2007 | 149 | 0.070 |
Why?
|
| Diastole | 1 | 2007 | 161 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 843 | 0.070 |
Why?
|
| Leukopenia | 1 | 2006 | 23 | 0.070 |
Why?
|
| Dactinomycin | 1 | 2006 | 31 | 0.070 |
Why?
|
| Vincristine | 1 | 2006 | 44 | 0.070 |
Why?
|
| Etoposide | 1 | 2006 | 64 | 0.070 |
Why?
|
| Child | 4 | 2021 | 6405 | 0.070 |
Why?
|
| Neutropenia | 1 | 2006 | 72 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2006 | 129 | 0.070 |
Why?
|
| Methotrexate | 1 | 2006 | 91 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 792 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2018 | 249 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2006 | 82 | 0.070 |
Why?
|
| South Carolina | 3 | 2020 | 2752 | 0.060 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 306 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 1040 | 0.060 |
Why?
|
| Cerebral Infarction | 2 | 2017 | 103 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2021 | 622 | 0.060 |
Why?
|
| Sex Factors | 2 | 2020 | 1266 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2006 | 332 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1426 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2017 | 239 | 0.060 |
Why?
|
| Acute Disease | 1 | 2004 | 658 | 0.050 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 694 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 296 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 286 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2022 | 138 | 0.050 |
Why?
|
| North America | 1 | 2021 | 112 | 0.050 |
Why?
|
| Maternal Mortality | 1 | 2021 | 16 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 157 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 109 | 0.040 |
Why?
|
| Observation | 1 | 2010 | 30 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 26 | 0.040 |
Why?
|
| Cause of Death | 1 | 2021 | 241 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2010 | 57 | 0.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 95 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 135 | 0.040 |
Why?
|
| Motor Activity | 2 | 2015 | 621 | 0.040 |
Why?
|
| Biometry | 1 | 2020 | 72 | 0.040 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 95 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 90 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 245 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 267 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 567 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 101 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 202 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 116 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2010 | 186 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 59 | 0.040 |
Why?
|
| Suction | 1 | 2017 | 33 | 0.040 |
Why?
|
| Vascular Access Devices | 1 | 2017 | 21 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 1342 | 0.040 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2017 | 63 | 0.040 |
Why?
|
| Aftercare | 1 | 2017 | 114 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 442 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Body Weight Maintenance | 1 | 2015 | 6 | 0.030 |
Why?
|
| Animals | 1 | 2012 | 20881 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Turkey | 1 | 2014 | 7 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2012 | 3187 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2279 | 0.030 |
Why?
|
| Social Participation | 1 | 2014 | 16 | 0.030 |
Why?
|
| Mechanical Thrombolysis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 274 | 0.030 |
Why?
|
| Automobile Driving | 1 | 2014 | 88 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 767 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 369 | 0.030 |
Why?
|
| Self Care | 1 | 2015 | 253 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2013 | 127 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 319 | 0.030 |
Why?
|
| Credentialing | 1 | 2012 | 23 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 504 | 0.030 |
Why?
|
| Perfusion | 1 | 2012 | 131 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 800 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 320 | 0.030 |
Why?
|
| Neurosurgery | 1 | 2012 | 42 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 446 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2014 | 346 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 411 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 79 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2011 | 57 | 0.020 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 80 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 1 | 2010 | 15 | 0.020 |
Why?
|
| Heart Valves | 1 | 2012 | 171 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 82 | 0.020 |
Why?
|
| Mortality | 1 | 2011 | 163 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2010 | 34 | 0.020 |
Why?
|
| Thrombophilia | 1 | 2010 | 21 | 0.020 |
Why?
|
| Embolism | 1 | 2010 | 45 | 0.020 |
Why?
|
| Patient Safety | 1 | 2012 | 202 | 0.020 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 86 | 0.020 |
Why?
|
| Overweight | 1 | 2010 | 186 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2010 | 249 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 737 | 0.020 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 191 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 365 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2012 | 657 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 186 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 364 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 1034 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2011 | 866 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 2324 | 0.010 |
Why?
|